肺表面活性蛋白A、D水平监测在间质性肺疾病诊治中的临床价值

Clinical value of pulmonary surfactant protein A and D in diagnosis and treatment of interstitial lung disease

目的探讨肺表面活性蛋白A、D(SP-A、SP-D)水平监测在间质性肺疾病诊治中的临床价值。方法选取从2013年6月到2015年7月治疗的118例间质性肺疾病患者作为观察组,另选取同期健康人群115例作为对照组。应用酶联免疫吸附实验(ELISA)法测定观察组患者急性加重期与病情缓解期痰液与血清中SP-A与SP-D的含量,评估其水平变化监测对于临床诊断与治疗的应用价值。结果观察组患者病情急性加重期痰液与血清中SP-A与SP-D水平均高于病情缓解期,观察组患者不同病情进展期血清及痰液中SP-A与SP-D水平均高于对照组患者,差异具有统计学意义(P<0.05)。结论临床实时监测间质性肺疾病患者SP-A与SP-D的变化水平,可用于该类疾病的早期诊断、临床监测病情进展情况及评价治疗效果与预后。

Objective To investigate the clinical value of pulmonary surfactant protein A,D（SP- A,SP- D） in diagnosis and treatment of interstitial lung disease.Methods 118 patients with interstitial lung disease admitted from June 2013 to July 2015 were selected as observation group.The levels of pulmonary surfactant protein A and D in the sputum and serum of the observation group were measured by enzyme-linked immunosorbent assay（ELISA）,and the changes of the levels of pulmonary surfactant protein A and D in the observation group were evaluated for the clinical diagnosis and treatment of acute exacerbation.Results SP- A and SP- D levels in the sputum and in serum of the patients in the observation group were higher than those in the remission stage.The levels of SP- A and SP- D in the sputum of the patients in the observation group were higher than those of the control group patients,the difference was statistically significant（P 〈0.05）.Conclusion The clinical real- time monitoring of serum pulmonary surfactant protein in patients with interstitial lung disease activity A,D levels can be used for diagnosis and diagnosis,clinical monitoring of the disease progress and treatment and prognosis of these diseases early.